IL-31 and IL-8 in Cutaneous T-Cell Lymphoma: Looking for Their Role in Itch
Table 1
Sociodemographic and clinical characteristics of the CTCL study population.
Age (years)
66 (36–90)
Gender (male/female)
14 (51.9%)/13 (48.1%)
CTCL classification
Mycosis Fungoides
17 (63.0%)
Sézary syndrome
10 (37.0%)
Time of evaluation
At the diagnosis
5 (18.5%)
During disease follow-up
22 (81.5%)
Skin lesions, at the time of the study
Patches
17 (63.0%)
Plaques
8 (29.6%)
Papules
2 (7.4%)
Nodules
1 (3.7%)
Tumors
1 (3.7%)
Erythroderma
9 (33.3%)
Body surface area affected, at the time of the study
<10
8 (29.6%)
[10–80%]
8 (29.6%)
≥80%
11 (40.7%)
Disease stage, at the time of the study
Stages I and II
18 (66.7%)
Stages III and IV
9 (33.3%)
Pruritus, at the time of the study
Yes (score 1 to 10)
18 (66.7%)
Mild/moderate (score 1 to 5)
7 (25.9%)
Intense/severe (score 6 to 10)
11 (40.7%)
VAS score, all patients
1 (0–10); 4 ± 4
VAS score, early disease/advanced disease
1 (0–10); 2 ± 3/10 (5–10); 9 ± 2
VAS score, MF patients/SS patients
0 (0–10); 2 ± 3/9 (1–10); 8 ± 3
Treatment, at the time of the study
Directed to the disease
18 (66.7%)
Directed to itch
19 (70.4%)
Results are presented as median (range), mean ± standard deviation, and as absolute and relative frequencies. CTCL, cutaneous T-cell lymphoma; MF, Mycosis Fungoides; SS, Sézary syndrome; VAS, visual analogue scale. One SS patient bore no erythroderma at the time of the evaluation.
